Revisiting our top six stocks for February

About the author:

Author name:

By Fiona Buchanan

Job title:

Co-Head of Research, Senior Analyst

Date posted:

03 March 2014, 7:50 AM

Sectors Covered:

Property, AREITS

Last month we shared our Six top 100 stocks to buy in February - companies we expected to outperform the market based on short to medium-term catalysts.

Our picks were published on February 4, and the ASX had a pretty good run (returning 6.9%) from then until the end of the month. We thought it timely to revisit our selections, and we're pleased to say the share prices for our six stocks increased on average by 13.1% during the same period. 

The big winners were SEEK (SEK) and Flight Centre (FLT), but most of our picks have performed well:

Crown (CWN)

• share price at February 4 close - $16.29
• share price at February 28 close - $17.28
• total return - 6%

Harvey Norman (HVN)

• share price at February 4 close - $2.93
• share price at February 28 close - $3.21
• total return - 9.5%

Sonic Healthcare (SHL)

• share price at February 4 close - $16.20
• share price at February 28 close - $17.37
• total return - 7.2%

Flight Centre (FLT)

• share price at February 4 close - $45.70
• share price at February 28 close - $51.85
• total return - 13.5%

SEEK (SEK)

• share price at February 4 close - $12.31
• share price at February 28 close - $17.11
• total return - 39%

Sydney Airport (SYD)

• share price at February 4 close - $3.92
• share price at February 28 close - $4.06
• total return - 3.5%

Our stock picks for March

We'll be publishing our top picks for March in the next few days. Keep an eye on the Morgans blog for the details.

More information

Morgans clients can access detailed reports on all our high conviction stock picks. If you would like more information, please contact your nearest Morgans office.

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.